Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma

EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling

(2012) Kristy J. Wilson et al.   GROWTH FACTORS

Tissue Biomarkers for Prognosis in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis

(2011) N. B. Jamieson et al.   CLINICAL CANCER RESEARCH

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma

(2011) Nardin Samuel et al.   Nature Reviews Gastroenterology & Hepatology

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer

(2010) Gilda da Cunha Santos et al.   CANCER

Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report

(2009) M. J. Duffy et al.   ANNALS OF ONCOLOGY

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

(2009) Rafael Rosell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop

(2008) Nicole E. Willmarth et al.   CELLULAR SIGNALLING

New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways

(2008) H. Burris et al.   ONCOLOGIST